Immunotherapy for the treatment of gastrointestinal cancer.
Posted by giorgiobertin on July 7, 2023
Gastrointestinal (GI) cancers, including the esophageal, gastroesophageal junction, gastric, duodenal, and distal small intestine, biliary tract, pancreas, colon, rectum, and anal, comprise a heterogeneous group of malignancies.
Immunotherapy has transformed the treatment landscape for several gastrointestinal cancers, offering some patients durable responses and prolonged survival. In particular, immune checkpoint inhibitors (ICIs) directed against programmed cell death protein 1 (PD-1)both as monotherapies and in combination regimens, have gained specific regulatory approvals for the treatment of metastatic disease and in the resectable setting.
La Society for Immunotherapy of Cancer (SITC) ha sviluppato these guidelines of clinical practice on immunotherapy for the treatment of gastrointestinal cancer. The document includes biomarker testing, therapy selection, patient education, and quality of life considerations.
Download and read the full text of the article:
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
Kelly RJ, Bever K, Chao J, et al
Journal for ImmunoTherapy of Cancer 2023;11:e006658. doi: 10.1136/jitc-2022-006658
I like:
“Like” Loading…
Related
This entry was posted on luglio 7, 2023 a 6:14 am and is filed under News-search. Marked by tags: Gastroenterology, immunology, oncology. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a responseor trackback from your own site.